Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October ...
August 23, 2019 16:06 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
August 08, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

Top-line Phase 2 refractory status epilepticus (RSE) data on-track for Q3 2019 Scott Braunstein, MD appointed as CEO Nicole Vitullo appointed as Chairman of the Board RADNOR, Pa., Aug. 08, 2019 ...
July 23, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression

Second proof-of-concept study for IV ganaxolone with clinically meaningful activity Ganaxolone IV and oral formulations were safe and well-tolerated Future development in severe depressive disorders...
June 19, 2019 16:00 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

RADNOR, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
June 03, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences

RADNOR, Pa., June 03, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
May 01, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results

RADNOR, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
March 11, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results

RADNOR, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
March 06, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative...
March 05, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference

RADNOR, Pa., March 05, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to...